Accéder au contenu
MilliporeSigma
  • Inhibition of sphingosine kinase prevents lipopolysaccharide-induced preterm birth and suppresses proinflammatory responses in a murine model.

Inhibition of sphingosine kinase prevents lipopolysaccharide-induced preterm birth and suppresses proinflammatory responses in a murine model.

The American journal of pathology (2015-01-13)
Vibhuti Vyas, Charles R Ashby, Nicole S Olgun, Sruthi Sundaram, Oluwabukola Salami, Swapna Munnangi, Ryan Pekson, Prathamesh Mahajan, Sandra E Reznik
RÉSUMÉ

Premature delivery occurs in 12% of all births, and accounts for nearly half of long-term neurological morbidity, and 60% to 80% of perinatal mortality. Despite advances in obstetrics and neonatology, the rate of premature delivery has increased approximately 12% since 1990. The single most common cause of spontaneous preterm birth is infection. Several lines of evidence have demonstrated the role of endothelin-1 as both a constrictor of uterine myometrial smooth muscle and a proinflammatory mediator. Endothelin-1 activates the phospholipase C pathway, leading to activation of protein kinase C and, in turn, sphingosine kinase (SphK). The inhibition of SphK has been recently shown to control the proinflammatory response associated with sepsis. We show herein, for the first time, that SphK inhibition prevents inflammation-associated preterm birth in a murine model. Rescue of pups from premature abortion with an SphK inhibitor occurs by suppression of the proinflammatory cytokines tumor necrosis factor α, Il-1β, and Il-6 and attenuation of polymorphonuclear inflammatory cells into the placental labyrinth. Moreover, we postulate that inhibition of SphK leads to suppression of endothelin-converting enzyme-1 expression, indicating the presence of an endothelin-converting enzyme 1/endothelin 1-SphK positive feedback loop. This work introduces a novel approach for the control of infection-triggered preterm labor, a condition for which there is no effective treatment.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
MOPS, ≥99.5% (titration)
Sigma-Aldrich
o-xylène, puriss. p.a., ≥99.0% (GC)
Sigma-Aldrich
MOPS, BioPerformance Certified, suitable for cell culture, ≥99.5% (titration)
Sigma-Aldrich
o-xylène, reagent grade, ≥98.0%
Sigma-Aldrich
L-Lysine monohydrochloride, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
MOPS, BioXtra, ≥99.5% (titration)
Sigma-Aldrich
Hematoxylin
Supelco
o-xylène, suitable for HPLC, 98%
Sigma-Aldrich
DL-Glyceraldehyde 3-phosphate solution, 45-55 mg/mL in H2O
Sigma-Aldrich
Hematoxylin, certified by the Biological Stain Commission
SAFC
MOPS
Sigma-Aldrich
o-xylène, anhydrous, 97%
Sigma-Aldrich
L-Lysine monohydrochloride, reagent grade, ≥98% (HPLC)
Supelco
o-xylène, analytical standard
Sigma-Aldrich
MOPS, anhydrous, free-flowing, Redi-Dri, ≥99.5%
Sigma-Aldrich
MOPS, BioUltra, for molecular biology, ≥99.5% (titration)
Supelco
L-Lysine monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Lysine monohydrochloride, BioUltra, ≥99.5% (AT)
Lysine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
o-xylène, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-Lysine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard
Supelco
L-Lysine monohydrochloride, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland